Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities:
Net income (loss)	$ (59,212)	$ 9,639
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Non-cash impairment charge	104,245
Non-cash share-based compensation expense	18,912	16,111
Non-cash interest expense	7,385	6,882
Non-cash charge for contingent consideration	1,548	3,594
Non-cash charge for option amortization	3,547	2,740
Non-cash charge for loan loss allowance	1,651
Non-cash investment premium amortization	754	1,380
Deferred tax provision	(51,544)	(23,409)
Depreciation and amortization expense	26,656	28,560
Other, net	(3,437)	(847)
Changes in assets and liabilities:
Accounts receivable	13,323	27,327
Inventory	(33,881)	4,799
Prepaid expenses and other current assets	(2,405)	(2,655)
Prepaid income taxes and income taxes payable	11,428	452
Other assets	(4,736)	(13,478)
Accounts payable	(5,482)	(1,757)
Accrued expenses and other current liabilities	(12,754)	13,306
Other non-current liabilities	2,372	2,156
Net cash provided by operating activities	18,370	74,800
Cash flows from investing activities:
Purchase of Lev Pharmaceuticals, Inc.		(91,404)
Purchase of property, equipment and building improvements	(1,412)	(1,171)
Purchase of short-term investments	(49,807)	(92,636)
Maturities of short-term investments	50,782	121,874
Net cash used in investing activities	(437)	(63,337)
Cash flows from financing activities:
Payment for treasury shares acquired		(151,895)
Net proceeds from issuance of common stock	8,934	9,174
Excess tax benefits from share-based payment arrangements	2,352	5,417
Net cash provided by (used in) financing activities	11,286	(137,304)
Effect of exchange rate changes on cash	849	220
Net increase (decrease) in cash and cash equivalents	30,068	(125,621)
Cash and cash equivalents at beginning of period	175,518	331,352
Cash and cash equivalents at end of period	$ 205,586	$ 205,731